Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Delivery
- Medical
- Device
- Drugs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 164315
Licensor grants the Licensee a non-exclusive license, or, if applicable, sublicense, to use the Licensors Trademarks, upon or in relation to the promotion, marketing, advertising, sale or offering for sale of the Licensors Royalty Products.
The Licensors Medipad System Patent Portfolio includes, among others, patents and applications for Method and Device for Entrapping a Volume of Gas in a Liquid Drug Container, Improved Method of Packaging a Drug Delivery Kit, Cartridge-Based Drug Delivery Device and Medicament Delivery Device.
Medipad/TM/ is a lightweight, disposable drug delivery system, which combines the simplicity of a patch with the extensive delivery capabilities of an infusion pump.
IPSCIO Record ID: 233493
The Licensor of Bermuda grants to the Licensee of Bermuda an exclusive license to the Licensors Background Technology and Licensors Improvements to package, import, use, offer for sale and sell and otherwise distribute the Product for the Field in the Territory.
Licensor also grants a non-exclusive license in the Territory to use the Licensors Trademark solely for the purposes of exercising its rights and performing its obligations under this Agreement.
The Compound shall mean any formulations of Desferoxamine and any of its analogues, isomers or derivatives.
The System shall mean the ambulatory subcutaneous infusion drug delivery system for direct attachment to the body of a patient having a flexible diaphragm drug reservoir, which is capable of delivering factory pre-programmed continuous amounts of drug upon activation as disclosed and described in the Licensors patents.
Deferoxamine (DFOA) is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.
IPSCIO Record ID: 240465
(i) an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed, except with respect to any Retained Licensor Intellectual Property, as to which Licensee is being granted a non-exclusive license
(ii) a non-exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed on Appendix E, and
(iii) subject to existing contractual rights of third parties, an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property for use with any other compounds not listed on Appendices D or E and which are not Licensor Compounds.
In each case for use only as Auto-Injector Technology and in the Field for the Territory to develop, make, have made, manufacture, have manufactured, package, use, import, export, promote, distribute, market, offer for sale, and sell the Devices and Products in the Field for the Territory.
Auto-Injector Technology shall mean any technology incorporated or used in a device (i) constituting a disposable, single use, needle injection system wherein the active ingredient is housed in a vial which is situated in a manner substantially perpendicular to the body surface, (ii) utilizing gas generation achieved via a chemical reaction for delivery of the active ingredient and (iii) having infusion time for delivery of an active ingredient which is less than or equal to 10 seconds. For the avoidance of doubt, Auto-Injector Technology shall not include any other technology that does not meet the foregoing definition, whether or not similar or containing elements of the Licensor Intellectual Property, including, without limitation, the Medipad(TM) Technology or any other Excluded Technology.
Licensor Know-How shall mean all knowledge, information, trade secrets, data and expertise relating to the Licensor Patents for use in the Field and that is owned or licensed by Licensor (other than the Excluded Technology) as of the Effective Date, including, but not limited to, clinical data and test results, whether or not covered by any patent, copyright, design, trademark, trade secret or other industrial or intellectual property rights, but, except as otherwise provided herein, all subject to any contractual obligations to unaffiliated third parties that Licensor has as of the Effective Date.
Joint Intellectual Property shall mean the Joint Know-How and/or the Joint Patent Rights.
Joint Patent Rights shall mean any patent and patent applications created, developed, conceived or otherwise jointly invented or developed by Licensor and Licensee, relating to the Auto-Injector Technology. Joint Patent Rights shall also include all extensions, continuations, continuations-in-part, divisionals, patents of additions, re-examinations, re-issues, supplementary protection certificates and foreign counterparts of such patents and patent applications and any patents issuing thereon and extensions of any patents licensed hereunder.
Licensor Compounds shall mean, at any time during the Term of this Agreement or, in the event of the acquisition of Licensor by another pharmaceutical company, immediately prior to the time of such acquisition, chemical entities (i) for which Licensor is the patent holder or which are in-licensed by Licensor or (ii) which are not patented and which Licensor is developing to sell itself In Market.
IPSCIO Record ID: 286035
The Licensor of Ireland shall remain proprietor of the Licensors Glucose Monitor Technology but grants to Licensee for the term a sole and exclusive license in the territory, with the right to grant sublicenses, to research, develop, manufacture, have manufactured for Licensee, import and have imported, use, sell, offer for sale and otherwise commercialize the Glucose Monitor Technology, Licensors interest in the joint improvements in the field and the products.
Licensor grants an exclusive license in the territory solely for use in connection with the sale of the product, for the term to use any Licensor trademark, if any, which relates to the Licensors Glucose Monitor Technology applicable to the product.
This agreement includes a non-exclusive grant back to Licensor from Licensee.
Licensor is knowledgeable in the development of devices and methods for directly or indirectly monitoring the concentration of glucose in a subject and has developed unique monitoring devices and methods.
The patents are for Analyte Controlled Liquid Delivery Device and Analyte Monitor; and, Improved Glucose Monitor.
